Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilgavimab/tixagevimab - AstraZeneca

Drug Profile

Cilgavimab/tixagevimab - AstraZeneca

Alternative Names: AZD 7442; AZD 8895 + AZD 1061; COV2-2196 + COV2-2130; Tixagevimab + Cilgavimab; Tixagevimab/Cilgavimab

Latest Information Update: 19 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vanderbilt University
  • Developer AstraZeneca
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 16 Mar 2021 AstraZeneca expects to receive Emergency Use Authorisation from the US FDA for prevention of COVID-2019 infections (in post-exposure prophylaxis)
  • 12 Feb 2021 National Institute of Allergy and Infectious Diseases plans a phase II/III ACTIV-2 trial for COVID-2019 infections in USA (IM) (NCT04518410)
  • 28 Jan 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in United Kingdom and Germany (IM) (NCT04723394), (EudraCT2020-005315-44)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top